Big pharma in big China

While many are jumping on the China bandwagon for less expensive manufacturing and research and development, the country is also developing low-cost medicines that seriously undercut U.S. prices and might just transform the U.S. drug industry entirely. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.